Journal of Clinical Endocrinology & Metabolism, Vol 77, 982-990, Copyright © 1993 by Endocrine Society

ARTICLES

Thyroid hormone resistance syndrome: correlation of dominant negative activity and location of mutations

T Nagaya, NL Eberhardt and JL Jameson
Thyroid Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114.

Generalized resistance to thyroid hormone (GRTH) is caused by multiple distinct mutations that cluster in two regions of the hormone-binding domain of the thyroid hormone beta-receptor. The mutant receptors are functionally inactive, but nevertheless inhibit normal receptor activity in a dominant negative manner. Four different GRTH mutants were studied in the transient expression assays to further examine their functional properties. The transcriptional activity of the mutant receptors correlated with their T3 binding affinities. Two distal region mutants with partial T3 binding were transcriptionally active at high T3 concentrations, but exhibited potent dominant negative activity at low T3 concentrations. Two proximal region mutants that did not bind to T3 were 5- to 10-fold less effective inhibitors of normal receptor function, indicating that dominant negative inhibition is not correlated with T3 binding activity. Each of the proximal and distal region mutants retain the ability to form heterodimers with accessory proteins and to bind to DNA effectively. Because the non-T3 binding thyroid hormone receptor isoform alpha 2 also exists in most tissues, its effects on mutant receptor function were also examined. The inhibitory activity of each of the GRTH mutants was potentiated by alpha 2 but only in the context of a positively regulated reporter gene. Thus, alpha 2 may selectively alter the degree of dominant negative activity that occurs for different target genes. We conclude that the locations of GRTH mutations may influence dominant negative activity by altering transactivating or other functions of the receptor, providing a potential basis for the phenotypic variability in different kindreds with GRTH.

This article has been cited by other articles:

				D. S. Machado, A. Sabet, L. A. Santiago, A. R. Sidhaye, M. I. Chiamolera, T. M. Ortiga-Carvalho, and F. E. Wondisford From the Cover: A thyroid hormone receptor mutation that dissociates thyroid hormone regulation of gene expression in vivo PNAS, June 9, 2009; 106(23): 9441 - 9446. [Abstract] [Full Text] [PDF]

				S. Cote, A. Rosenauer, A. Bianchini, K. Seiter, J. Vandewiele, C. Nervi, and W. H. Miller Jr Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells Blood, September 18, 2002; 100(7): 2586 - 2596. [Abstract] [Full Text] [PDF]

				S. A. Phillips, P. Rotman-Pikielny, J. Lazar, S. Ando, P. Hauser, M. C. Skarulis, F. Brucker-Davis, and P. M. Yen Extreme Thyroid Hormone Resistance in a Patient with a Novel Truncated TR Mutant J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5142 - 5147. [Abstract] [Full Text] [PDF]

				P. M. Yen Physiological and Molecular Basis of Thyroid Hormone Action Physiol Rev, July 1, 2001; 81(3): 1097 - 1142. [Abstract] [Full Text] [PDF]

				S. Cote, D. Zhou, A. Bianchini, C. Nervi, R. E. Gallagher, and W. H. Miller Jr Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia Blood, November 1, 2000; 96(9): 3200 - 3208. [Abstract] [Full Text] [PDF]

				H. L. Müller, M. Yamazaki, T. Michigami, T. Kageyama, E. Schönau, P. Schneider, and K. Ozono Asp361Val Mutant of Alkaline Phosphatase Found in Patients with Dominantly Inherited Hypophosphatasia Inhibits the Activity of the Wild-Type Enzyme J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 743 - 747. [Abstract] [Full Text]

				J. D. Safer, M. G. O’Connor, S. D. Colan, S. Srinivasan, S. R. Tollin, and F. E. Wondisford The Thyroid Hormone Receptor-{beta} Gene Mutation R383H Is Associated with Isolated Central Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3099 - 3109. [Abstract] [Full Text]

				T. Tagami, W.-X. Gu, P. T. Peairs, B. L. West, and J. L. Jameson A Novel Natural Mutation in the Thyroid Hormone Receptor Defines a Dual Functional Domain That Exchanges Nuclear Receptor Corepressors and Coactivators Mol. Endocrinol., December 1, 1998; 12(12): 1888 - 1902. [Abstract] [Full Text]

				J. D. Safer, R. N. Cohen, A. N. Hollenberg, and F. E. Wondisford Defective Release of Corepressor by Hinge Mutants of the Thyroid Hormone Receptor Found in Patients with Resistance to Thyroid Hormone J. Biol. Chem., November 13, 1998; 273(46): 30175 - 30182. [Abstract] [Full Text] [PDF]

				T. Tagami and J. L. Jameson Nuclear Corepressors Enhance the Dominant Negative Activity of Mutant Receptors That Cause Resistance to Thyroid Hormone Endocrinology, February 1, 1998; 139(2): 640 - 650. [Abstract] [Full Text] [PDF]

				S. M. Yoh, V. K. K. Chatterjee, and M. L. Privalsky Thyroid Hormone Resistance Syndrome Manifests as an Aberrant Interaction between Mutant T3 Receptors and Transcriptional Corepressors Mol. Endocrinol., April 1, 1997; 11(4): 470 - 480. [Abstract] [Full Text]

				J. D. Safer, M. F. Langlois, R. Cohen, T. Monden, D. John-Hope, J. Madura, A. N. Hollenberg, and F. E. Wondisford Isoform Variable Action among Thyroid Hormone Receptor Mutants Provides Insight into Pituitary Resistance to Thyroid Hormone Mol. Endocrinol., January 1, 1997; 11(1): 16 - 26. [Abstract] [Full Text]